🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re excited to announce the launch of OrsoBio as we embark on our mission to redefine the treatment of metabolic diseases. Special thanks to our scientific advisors (Dr. G. Shulman, Auwerx Lab, TAKEBE Takanori Laboratory) and SamsaraBioCapital for their support! bwnews.pr/3TacLqx

A new biotech just dropped with a basket of assets, including two clinical-stage ones, from Gilead, Shionogi, Phenex Pharmaceuticals, Astellas’ Mitobridge and Yale. endpts.com/samsara-backs-…

OrsoBio launched Tuesday with Gilead alums Mani Subramanian, M.D., in the CEO seat and Rob Myers, M.D., serving as chief medical officer. fiercebiotech.com/biotech/5-pres…

Today we announced dosing of the first patient in our Phase 2a trial of the ACC2-selective inhibitor TLC-3595 for the treatment of #diabetes. Read more about this important milestone: bwnews.pr/3TvGmw3

Today we announced a Phase 1 trial of the liver-targeted mitochondrial protonophore, TLC-6740, in development for treatment of #obesity and associated diseases (#NASH, #diabetes). Read more here: bit.ly/3MSGRgN

Today we announced Phase 1 data for our liver-targeted, mitochondrial protonophore, TLC-6740, at #ObesityWeek. Preliminary data suggest TLC-6740 is well tolerated and will reach therapeutic exposures at low doses. Read more here: tinyurl.com/OrsoBio #obesity #diabetes #NASH

Today we announced Ph 1 data for TLC-2716, a liver-targeted LXR inverse agonist in development for severe hypertriglyceridemia/#NASH, to be presented at #AHA23. The data demonstrate dose-dependent improvements in plasma TGs, LDL-C, LDL particles and apoB. bwnews.pr/3sweuii